Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/dc.21759 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plasmablastic multiple myeloma presenting as a pleural mass: a diagnostic challenge.
BMJ Case Rep
November 2024
Pathology, Hackensack Meridian Hackensack University Medical Center, Hackensack, New Jersey, USA.
Plasmablastic multiple myeloma (MM) is a rare and highly aggressive variant of MM that presents significant diagnostic and therapeutic challenges. This variant is characterised by a bone marrow infiltration of ≥2% plasmablasts and is distinguished by its atypical pleomorphic morphology, unique immunohistological profile and extensive extramedullary involvement. The anaplastic features of plasmablastic MM can closely mimic those of high-grade lymphomas, leukaemia, non-haematopoietic malignancies and high-grade carcinomas, often leading to initial diagnostic errors.
View Article and Find Full Text PDFExtraosseous manifestations are found in less than 5% of patients with multiple myeloma. They can arise in any tissue, and their presence has been associated with more aggressive disease. We present FDG PET/CT findings of immunoglobulin A κ multiple myeloma with innumerable hypermetabolic right lower extremity lesions of cutaneous and subcutaneous involvement of plasmablastic plasma cell myeloma in a 44-year-old man.
View Article and Find Full Text PDFBCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review.
Crit Rev Oncol Hematol
January 2025
Department of Myeloma and Lymphoma, Beijing GoBroad Boren Hospital, Beijing 100070, China; Beijing Branch Center of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100070, China; Myeloma Research Institute, Beijing GoBroad Boren Hospital, Beijing 100070, China. Electronic address:
Article Synopsis
- Richter transformation poses a continued risk for chronic lymphocytic leukemia (CLL) patients, even with advancements in targeted therapies like Bruton's tyrosine kinase inhibitor, particularly in a reported case of a 61-year-old male who experienced this change post-treatment.
- After stopping ibrutinib during the COVID-19 pandemic, the patient developed a related plasmablastic lymphoma (PBL), diagnosed through histological analysis of a tumor in the supraclavicular area and bone marrow infiltration.
- The patient underwent treatment with a combination of CHP, venetoclax, and brentuximab vedotin, followed by successful BCMA CAR-T cell therapy, resulting in complete remission and highlighting the potential
Epstein-Barr virus-positive plasmacytoma in an immunocompetent female: A case report.
J Clin Exp Hematop
September 2024
Department of Pathology, University of Yamanashi, Chuo, Yamanashi, Japan.
Plasmacytoma is defined as a plasma cell neoplasm forming a solitary osseous or extramedullary tumor without evidence of myeloma or organ damage related to a plasma cell neoplasm. Epstein-Barr virus (EBV) is associated with various B-cell neoplasms, particularly in patients with immune dysregulation; however, plasmacytoma is typically negative for EBV. Here, a case of EBV-positive sternal plasmacytoma in an immunocompetent female is presented.
View Article and Find Full Text PDFUnusual plasmablastic subtype of multiple myeloma in a young adult.
Intern Emerg Med
September 2024
Department of Anatomical Pathology and Cytopathology, Universidad Autónoma de Nuevo León, Av. Francisco I. Madero S/N, Mitras Centro, 64460, Monterrey, Nuevo León, Mexico.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!